GHRP-2, or Growth Hormone Releasing Peptide-2, is a synthetic hexapeptide that belongs to a class of growth hormone secretagogues (GHS) and operates by stimulating the pituitary gland to increase the production of endogenous growth hormone (GH).
Its action mechanism primarily involves the activation of the ghrelin/growth hormone secretagogue receptor (GHSR), which leads to an increased release of GH. Additionally, it inhibits somatostatin, a hormone that negatively regulates GH secretion.
In terms of clinical applications, GHRP-2 peptide has shown potential in treating conditions related to GH deficiency, muscle wasting diseases, and certain metabolic disorders. Furthermore, Finland research suggests that given its property to stimulate appetite, it could be used in managing eating disorders and cachexia.
Showing all 5 results
SALE
[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2824650/
[2] https://pubmed.ncbi.nlm.nih.gov/7858486/
[3] https://pubmed.ncbi.nlm.nih.gov/15507538/
[4] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2795722/
[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1856079/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://finland.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States